DexCom, Inc. (DXCM) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Robust Q2 2025 growth with 15% organic revenue increase; launch of Stelo OTC continuous glucose monitor; strong operating cash flow and liquidity (~$2.9B cash); bullish technical momentum with recent 8% price gain and price near $71-$72 resistance; upcoming earnings on October 30 an important catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High profitability ⢠Heavy investment DexCom pairs strong profitability, high gross margins and solid FY2025 free cash flow with significant R&D/capex and premium valuations that heighten downside risk if growth or margins slip. Valuation: Shares trade at premium multiples (P/E ~30, P/B ~9, EV/EBITDA ~18.8), leaving limited margin for error and requiring continued growth to justify the price.
Price Behavior
Key Price Behavior Insights: ⢠Below moving average ⢠Strongly oversold ⢠Recent low critical Support Level: Not provided in text (recent low on 2026-03-13 and secondary near 2026-02-12) Resistance Level: $73â$74 DXCM is trading well below its last-month SMA with a mid-teens (â17) RSI signalling strong oversold conditions and a likely short-term bounce unless the recent 2026-03-13 low (and Feb low) gives way.
Sentiment & News
Key News Insights: ⢠Institutional buying ⢠Margin upside ⢠Governance probe Renewed institutional buying, upbeat analyst sentiment and expected margin/product tailwinds boost DexCom's momentum, tempered by some fund selling and an active shareholder fiduciary probe.
AI Summary
DexCom is now a transition stock: its premium valuation is only justified if nearâterm manufacturing fixes and freight normalization deliver the ~200bps grossâmargin recovery and payer wins in typeâ2, otherwise remediation delays, litigation or slower formulary uptake will quickly compress multiples.
Description
DexCom, Inc. develops, manufactures and sells continuous glucose monitoring systems for people with diabetes and for use by healthcare providers worldwide. Its product portfolio includes current and next-generation wearable CGM devices and software that enable real-time glucose data sharing and integration with third-party digital health tools; the company also maintains a collaboration with Verily on glucose-monitoring technologies. Founded in 1999, DexCom is headquartered in San Diego, California and sells its products directly to clinicians and patients.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Oct 27 | Nov 3 | DXCM | DexCom, Inc. | Robust Q2 2025 growth with 15% organic revenue increase; launch of Stelo OTC continuous glucose monitor; strong operating cash flow and liquidity (~$2.9B cash); bullish technical momentum with recent 8% price gain and price near $71-$72 resistance; upcoming earnings on October 30 an important catalyst. | Closed | -14.4% |